CTIS2023-506998-35-00进行中（未招募）1 期
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune) - TMZ-LOM
Vaestra Goetalandsregionen0 个研究点目标入组 190 人开始时间: 2023年12月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Written informed consent, Adequate organ function as described in the protocol, Patients on anticoagulation can be included at the discretion of the investigator, but oral anticoagulants, including NOAC/DOAC are recommended to be switched to Low-molecular-weight heparin (LMWH) during the treatment phase and until platelets are >50 or according to local guidelines., Patient capable of understanding the rationale and necessity of study therapy and procedures., Newly diagnosed histologically proven GBM, giant-cell GBM or gliosarcoma WHO Grad 4, histology confirmed by the local neuropathologist as IDHwt. Histology obtained by complete resection, partial resection, open biopsy or stereotactic biopsy., Methylated MGMT promoter in the tumor as determined according to local routine. For centers using the same method/kit the same cut-off for mMGMT will be used., Males or females 18-75 years of age, estimated life expectancy of at least 12 weeks, WHO Performance Score 0-2, Patient compliance and geographic proximity that allow adequate follow up, Male and female patients with reproductive potential must use an approved contraceptive method (intrauterine device, birth control pills, or barrier device) during and for 6 months after end of chemotherapy (Pearl index <1%), Pre-menopausal female patients with childbearing potential: a negative serum pregnancy test must be obtained within 14 days prior to treatment start
排除标准
- •Prior malignancy (except adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer), unless the prior malignancy was diagnosed and curatively treated =3 years previously with no subsquent evidence of recurrence, Any active infection (at the discretion of the investigator), Female patients that are breastfeeding and not willing to refrain, Patients with reproductive potential who do not accept to use contraception during chemotherapy and 6 months thereafter, Treatment in another clinical trial with oncological therapeutic intervention or use of any other investigational agent within 30 days before enrolment, Any psychological, cognitive, familial, social or geographical condition potentially hampering compliance with the study protocol and follow-up scheduled visits (at the discretion of investigator), Prior systemic chemotherapy with DNA-damaging agents for any cancer, Prior RT to the brain, Concurrent administration of any other antitumor therapy not described in the protocol, Concurrent administration of complementary or alternative drugs, Allergy or intolerability of temozolomide, dacarbazine, lomustine or other nitrosourea derivatives including celiac disease and wheat allergy, Unable to perform MRI, Past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, heart failure (NYHA III/IV), severe and poorly controlled diabetes, immune deficiency, residual deficits after stroke or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), Severly reduced lung function (at the discretion of the investigator)
研究者
相似试验
进行中（未招募）
1 期
Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG)ewly diagnosed patients with glioblastoma harbouring a methylated MGMT promoterMedDRA version: 18.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011252-22-DEMedical Faculty, University of Bonn
进行中（未招募）
1 期
Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy aloneEUCTR2004-001749-13-ATAESCA Pharma GesmbH92
已完成
3 期
A randomised phase III Trial on concurrent and adjuvant Temozolomide chemotherapy in non 1p/19q deleted anaplastic glioma to evaluate overall survival.Anaplastic GliomaNeurological - Other neurological disordersCancer - Other cancer typesACTRN12609000485235niversity of Sydney751
进行中（未招募）
1 期
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.anaplastic gliomaMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-001533-17-NLEORTC European Organisation for research and treatment of cancer751
进行中（未招募）
1 期
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.anaplastic gliomaMedDRA version: 9.1 Level: LLT Classification code 10018337 Term: Glioblastoma multiformeEUCTR2006-001533-17-ESEORTC European Organisation for research and treatment of cancer748